Compass pathways stock forecast.

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ... Future criteria checks 0/6. COMPASS Pathways's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be -82.5% in 3 years.Compass Pathways : ... However, the expert forecasts the stock moving up to $25, implying 252% upside potential. If so, FAT would easily be one of the sin stocks to buy.CMPS - COMPASS PATHWAYS PLC. AMERICAN DEPOSITORY SHARES. HOME · Internacional · Stocks ... ASSINATURAS PLANO BULL MÓDULO FORECAST. STATUS INVEST Política de ...

Compass Pathways has released the strongest evidence yet that psilocybin can improve outcomes in patients with treatment-resistant depression, linking its COMP360 candidate to a sharp improvement ...The 10 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 33.00, with a high estimate of 120.00 and a low estimate of 19.00. This indicates a potential increase of 254.08% from the last recorded price of 9.32. The consensus among 11 polled investment analysts is to buy stock in Compass …Web

LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...Nov 29, 2022 · That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51% ...

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ...WebFuture criteria checks 0/6. COMPASS Pathways's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be -82.5% in 3 years.An in-depth look at the leading psychedelic stocks in the U.S stock market this year. Here’s what you need to know. ... Compass Pathways (NASDAQ:CMPS) $350.9 million Developing one psilocybin ...In the last 3 months, 4 analysts have offered 12-month price targets for Compass Pathways. The company has an average price target of $53.75 with a high of $120.00 and a low of $19.00.EF Hutton analyst Elemer Piros reiterated a Buy rating on COMPASS Pathways (CMPS – Research Report) today and set a price target of $38.00... EF Hutton analyst Elemer Piros reiterated a Buy rating on COMPASS Pathways (CMPS – Research ...

Compass Pathways has released the strongest evidence yet that psilocybin can improve outcomes in patients with treatment-resistant depression, linking its COMP360 candidate to a sharp improvement ...

Can Compass Pathways' Stock Gain 458% Like Wall Street Is Expecting? This Regulatory Change Means Psychedelic Stocks Are One Step Closer to Being a …

The upgrade of COMPASS Pathways PLC Sponsored ADR to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move ...Current. -$0.61. 1 Month Ago. -$0.60. 3 Months Ago. -$0.65. COMPASS Pathways PLC ADR analyst estimates, including CMPS earnings per share estimates and analyst recommendations.Biotechnology firm COMPASS Pathways (CMPS) Wednesday announced a private placement of 16.08M American Depositary Shares and warrants to purchase up to 16.08M ADSs at a price of $7.78...Current. -$0.61. 1 Month Ago. -$0.60. 3 Months Ago. -$0.65. COMPASS Pathways PLC ADR analyst estimates, including CMPS earnings per share estimates and analyst recommendations.Find the latest analyst research for COMPASS Pathways Plc American Depository Shares (CMPS) at Nasdaq.com.Web

Detailed statistics for COMPASS Pathways plc (CMPS) stock, including valuation metrics, financial numbers, share information and more. ... Analyst Forecast. The ...COMPASS PATHWAYS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie COMPASS Pathways PLC (spons. ADRs) | A2QCDR | CMPS | US20451W1018 Despite the potential of EVgo, Inc. (EVGO), Amyris, Inc. (AMRS), and COMPASS Pathways plc (CMPS) springing a surprise during the earnings season, their less-than-ideal fundamentals deem it wise to avoid placing any long-term bets on these heavily shorted stocks.In 2021, easy money, unprecedented hype created by retail …18 ก.ย. 2563 ... That was up from initial expectations for $14-$16 announced earlier in the week, putting the valuation at about $544 million. Compass said it ...CMPS Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $50.17 with a high forecast of $120.00 and a low forecast of $21.00. The average price target represents a 832.53% change from the last price of $5.38. Nov 9, 2021 · What happened. Compass Pathways ( CMPS 6.61%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ...

Find the latest Alpha Lithium Corporation (APHLF) stock quote, history, news and other vital information to help you with your stock trading and investing.With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ...

Discover COMPASS Pathways' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers.While Compass Pathways' (CMPS 0.84%) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by 458% to reach around $42.30 within the next 12 months.Nonetheless, Atai remains one of the leaders in the psychedelics segment of the biotech industry, and it holds a 22.4% stake in Compass Pathways, which is one of the other leaders. So if Compass ...WebWall Street Stock Market & Finance report, prediction for the future: You'll find the Compass Pathways Plc - ADR share forecasts, stock quote and buy / sell signals below. According to present data Compass Pathways Plc - ADR's CMPS shares and potentially its market environment have been in bearish cycle last 12 months (if exists).An easy way to get COMPASS Pathways Plc - American Depository Shares real-time prices. View live CMPS depositary receipt chart, financials, and market news.The stock spiked 2.01% in intraday trading to $6.10 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is -5.43%, and it has moved by 5.54% in 30 days. Based on these gigs, the overall price performance for the year is -40.78%. The short interest in Compass Pathways Plc ADR (NASDAQ:CMPS) is 3.91 million shares ...Real time Compass Pathways Plc (CMPS) stock price quote, stock graph, news & analysis. COMPASS Pathways plc (CMPS) share price prediction for 2023, 2024, 2025, 2026 and 2027. CMPS one year forecast. Compass Pathways Plc stock monthly and weekly forecasts.WebShares of psychedelics-inspired medicine developer COMPASS Pathways (NASDAQ: CMPS) jumped more than 5% on Monday, ... CMPS Stock Price Forecast. Long-term, we love COMPASS Pathways.WebFeb 7, 2023 · 3. Compass Pathways. Compass Pathways (CMPS 6.61%) isn't a large holding for Wood. The psychedelic stock makes up less than 1% of her Ark Genomic Revolution ETF's portfolio. However, Compass ...

16 de ago. de 2023 ... The psychedelics biotech firm is set to receive $125 million selling stocks upfront, with a potential addition of $160 million from ...

May 26, 2023 · COMPASS Pathways is looking at the long-term effects of COMP360 in our phase 3 programme in treatment-resistant depression.” Manish Agrawal, MD, Chief Executive Officer, Sunstone Therapies, and the trial’s Principal Investigator, said: “This pioneering study is the first of its kind, conducted within a community hospital cancer center.

We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. News & events. News releases. SEC filings & annual reports. Our annual review. Stock information. Stock quote & chart. Historical price lookup. Corporate governance.WebCompare with up to 5 Stocks. On Thursday 11/30/2023 the closing price of the COMPASS Pathways PLC (spons. ADRs) share was $6.20 on NAS. Compared to the opening price on Thursday 11/30/2023 on NAS ...18 ก.ย. 2563 ... Stock Forecast / Price Prediction / Prognosis: Compass Pathways Plc - ADR Forecast. Predictions, Comments & Questions.Compass Pathways plc is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Compass Pathways plc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Compass Pathways plc or its management.Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ...WebPsychedelics biotech giant COMPASS Pathways (NASDAQ:CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select group ...The consensus 12-month price target for Compass Pathways reflects an upside potential of close to 325%. Even the most pessimistic analyst surveyed by Refinitiv thinks that the stock will double ...

Stay up to date on the latest Compass Pathways Plc (CMPS) stock price, market cap, PE ratio and real-time price movements. Buy CMPS shares with Stake.It may have a tough pill to swallow, but I'm still optimistic about psilocybin in general, and especially Cybin....CMPS At the time of publication, Tim Collins was long CYBN. Look how quickly we got bulled up. Let's check sentiment, the...The average price target is $46.83, with a high forecast of $120.00 and a low forecast of $19.00. ... The current consensus among 5 investment analysts is to buy stock in COMPASS Pathways. This Buy consensus rating has held steady for over two years. Past Monthly Recommendations.Aug 26, 2023 · Beam Therapeutics (BEAM-1.72%), COMPASS Pathways (CMPS-6.05%), ... The average price target for the stock is $41.67, implying a 382% upside potential from its current share price. Like Beam ... Instagram:https://instagram. trader funding programis visa a good stock to buybrokerage account taxpbt stock price Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. futures trading on robinhoodfig etf First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022 . Compass Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the Phase 3 pivotal program design for COMP360 psilocybin therapy in … what is the best dental insurance in california Dec 1, 2023 · CMPS Earnings Date and Information. COMPASS Pathways last posted its quarterly earnings results on November 2nd, 2023. The reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.17. COMPASS Pathways has generated ($2.59) earnings per share over the last year ( ($2.59) diluted earnings per share). COMPASS Pathways PLC (CMPS) stock is down -1.77% while the S&P 500 is higher by 1.89% as of 2:59 PM on Thursday, Apr 27. CMPS has fallen -$0.15 from the previous closing price of $8.17 on volume of 236,713 shares. Over the past year the S&P 500 has fallen -1.22% while CMPS has fallen -21.27%. CMPS lost -$0.01 per share the over the last 12 months.